Dr. Erin Blake is a gynecological oncologist at c-Care in northeast Fresno. She explains that it's often hard to detect ...

Stage 2 ovarian cancer means the cancer is present in one or both ovaries and has spread to other pelvic tissues, such as the ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Ovarian cancer. It's often called the silent killer because its symptoms can be so easy to overlook. It's one of the top leading causes of cancer deaths among women. Yet awareness, early detection, ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Ovarian cancer is increasingly affecting younger Indian women, with metro cities seeing a sharp rise. Late diagnoses are ...

International outcomes in breast, cervical, and ovarian cancers highlight opportunities to improve health-care delivery for ...

Without an easy way to screen and with nondescript symptoms, ovarian cancer is often caught in late stages, requiring massive ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6 mg/kg dose into the phase 3 part of the trial. The ORR ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...